Epigral Limited has submitted a regulatory disclosure to the National Stock Exchange of India Limited and BSE Limited regarding its participation in an investor conference. The disclosure is made pursuant to Regulation 30 and Para (A) of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company officials will be participating in EMKAY Confluence 2026, which is scheduled for Wednesday, 12th August, 2026, in Mumbai. The disclosure serves as an intimation to the exchanges for information of their members.
The letter was digitally signed by Gaurang Ghanshyam Trivedi, Company Secretary & Compliance Officer (Membership No. A22307) of Epigral Limited, on August 7, 2026, at 16:36:41 IST.
Financial Impact
No financial impact disclosed. This is a routine disclosure of corporate participation in an investor conference.